礼节
发表于 2025-3-23 11:53:23
ICH S9: Nonclinical Evaluation of Anticancer Pharmaceuticals: A Perspective from Regulators on the
使尴尬
发表于 2025-3-23 14:07:46
Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals: ICH M3 an
合群
发表于 2025-3-23 20:50:40
AAPS Advances in the Pharmaceutical Sciences Series386019.jpg
栏杆
发表于 2025-3-23 22:58:35
http://reply.papertrans.cn/39/3861/386019/386019_14.png
FOVEA
发表于 2025-3-24 03:21:57
978-1-4899-9407-3American Association of Pharmaceutical Scientists 2013
百科全书
发表于 2025-3-24 06:55:42
http://reply.papertrans.cn/39/3861/386019/386019_16.png
Confidential
发表于 2025-3-24 13:54:32
http://reply.papertrans.cn/39/3861/386019/386019_17.png
GIST
发表于 2025-3-24 18:30:25
http://reply.papertrans.cn/39/3861/386019/386019_18.png
FELON
发表于 2025-3-24 22:09:22
Book 2013esting, Genotoxicity Testing, etc.). Since the start of the ICH process, many guidelines have been written, but even after ICH6 no explanations have been given during a formal Congress about the background of the ICH Guidance documents. Even more important than what has been written, might have been
斜
发表于 2025-3-25 01:01:00
http://reply.papertrans.cn/39/3861/386019/386019_20.png